WO2023284778A1 - 一种益生元组合物及其应用 - Google Patents
一种益生元组合物及其应用 Download PDFInfo
- Publication number
- WO2023284778A1 WO2023284778A1 PCT/CN2022/105423 CN2022105423W WO2023284778A1 WO 2023284778 A1 WO2023284778 A1 WO 2023284778A1 CN 2022105423 W CN2022105423 W CN 2022105423W WO 2023284778 A1 WO2023284778 A1 WO 2023284778A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prebiotic composition
- oligosaccharide
- galacto
- fructo
- oligosaccharides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 74
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 51
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 51
- 210000002966 serum Anatomy 0.000 claims abstract description 39
- 201000010063 epididymitis Diseases 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 230000001603 reducing effect Effects 0.000 claims abstract description 22
- 239000002158 endotoxin Substances 0.000 claims abstract description 20
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 20
- 235000019786 weight gain Nutrition 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 230000037396 body weight Effects 0.000 claims description 23
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 22
- 229930182843 D-Lactic acid Natural products 0.000 claims description 18
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 18
- 229940022769 d- lactic acid Drugs 0.000 claims description 18
- 229940107187 fructooligosaccharide Drugs 0.000 abstract description 26
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract description 25
- 210000000918 epididymis Anatomy 0.000 abstract description 20
- 235000020824 obesity Nutrition 0.000 abstract description 16
- 230000004584 weight gain Effects 0.000 abstract description 4
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 abstract 1
- 239000000047 product Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 239000013641 positive control Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000013116 obese mouse model Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the invention belongs to the field of biotechnology, and in particular relates to a prebiotic composition and its application.
- Obesity is a chronic and complex disease closely related to common diseases in current society such as hyperlipidemia, type 2 diabetes, fatty liver, cardiovascular disease, cancer, etc. Excessive accumulation of fat will have adverse effects on body metabolism, physiological activities and mental health. Therefore, weight loss and obesity prevention are important areas of research for the management of many chronic diseases.
- Orlistat is currently a popular weight-loss product. It was approved in Europe in 1998 and is the only FDA-approved long-term treatment of obesity. It can inhibit gastrointestinal tract and pancreatic lipase and block triglycerides. Hydrolysis reduces the absorption of ingested fat. However, while reducing weight, it is accompanied by some unavoidable side effects such as fecal incontinence, excessive defecation, and oily stools. It is also necessary to supplement fat-soluble vitamins to avoid vitamin deficiency, and it will also reduce the diversity and richness of intestinal microorganisms.
- Prebiotics are a class of substances that are selectively utilized by microorganisms to confer health benefits on the host, including fructooligosaccharides (FOS), galactooligosaccharides (GOS), and the like. Regular intake of prebiotics such as fructo-oligosaccharides and galacto-oligosaccharides will increase the production of short-chain fatty acids by intestinal flora and increase the release of fat-eliminating peptides.
- FOS fructooligosaccharides
- GOS galactooligosaccharides
- the purpose of the present invention is to overcome the above-mentioned deficiencies in the prior art and provide a product that can be used to prepare products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing body weight gain, and products for reducing epididymal fat. products, prebiotic compositions for products in the emerging field of microecological medicine.
- the technical solution taken by the present invention is: a prebiotic composition comprising fructo-oligosaccharides and galacto-oligosaccharides.
- the prebiotic composition obtained by adopting the technical scheme of the present invention can be used to prepare products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing body weight gain, products for reducing epididymal fat, and products for emerging microbiota.
- Products in the field of ecological medicine, these products can effectively avoid the side effects of drugs for weight loss, accurately play the physiological role of prebiotic compositions, overcome the limitations of ambiguity and randomness in the application level of prebiotics, and provide biological solutions for precision nutrition and emerging microecological medicine.
- the application in the field of medicine provides a typical demonstration and helps to improve the prevention, control and treatment of obesity.
- the mass parts of the fructo-oligosaccharide is 100-900 parts, and the mass part of the galacto-oligosaccharide is 100-900 parts.
- the mass parts of the fructo-oligosaccharides are 300-900 parts, and the mass parts of the galacto-oligosaccharides are 100-700 parts.
- the mass parts of the fructo-oligosaccharide is 500-900 parts, and the mass part of the galacto-oligosaccharide is 100-500 parts.
- the mass parts of the fructo-oligosaccharides are 700-900 parts, and the mass parts of the galacto-oligosaccharides are 100-300 parts.
- Fructose-oligosaccharide is a natural active substance, which can regulate the micro-ecological balance of the human body in both directions. It is a typical super-strong bifidus factor; An effective proliferation factor that can improve the digestion and absorption function of the human intestinal tract.
- the present invention can achieve the effects that cannot be achieved by using the fructo-oligosaccharide and the galacto-oligosaccharide in combination.
- the preferred ratio is mainly based on the comprehensive reduction effect of the prebiotic composition on various obesity indicators. Among them, the prebiotic composition with 900 parts by mass of fructo-oligosaccharide and 100 parts by mass of galacto-oligosaccharide has the best comprehensive reduction effect on various obesity indexes.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of obesity-improving products.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products for reducing serum lipopolysaccharide and serum D-lactic acid.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products for reducing body weight gain.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products for reducing epididymal fat.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products used in the emerging microecological medical field.
- the present invention Compared with the prior art, the present invention has the following beneficial effects: the present invention provides a prebiotic composition, which includes fructo-oligosaccharide and galacto-oligosaccharide. At the same time, the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products for improving obesity, the application in the preparation of products for reducing serum lipopolysaccharide and serum D-lactic acid, the application in the preparation of products for reducing body weight gain, Application in preparation of products for reducing epididymis fat, and application in preparation of products for emerging microecological medical fields.
- a prebiotic composition which includes fructo-oligosaccharide and galacto-oligosaccharide.
- the present invention also provides the application of the above-mentioned prebiotic composition in the preparation of products for improving obesity, the application in the preparation of products for reducing serum lipopolysaccharide and serum D-lactic acid, the application in the preparation of products for reducing body weight gain, Application
- the prebiotic composition obtained by adopting the technical solution of the present invention can effectively improve the obesity index, avoid the side effects of weight loss drugs, accurately exert the physiological effects of the prebiotic composition, overcome the limitations of ambiguity and randomness in the application level of prebiotics, and provide accurate Applications in biomedical fields such as nutrition and emerging microecological medicine provide typical demonstrations, helping to improve the prevention, control, treatment and rehabilitation of obesity.
- Fig. 1 is the effect diagram of the effect of the prebiotic composition on the weight gain of the obese mouse model in Example 6;
- Fig. 2 is the effect figure that the prebiotic composition affects the epididymis fat index of obese mouse model in embodiment 6;
- Fig. 3 is the effect figure that prebiotic composition influences Lee index of obese mouse model in embodiment 6;
- Figure 4 is an effect diagram of the effect of the prebiotic composition on the serum lipopolysaccharide content of the obese mouse model in Example 6;
- Fig. 5 is a graph showing the effect of the prebiotic composition in Example 6 on the serum D-lactic acid content of an obese mouse model.
- a prebiotic composition according to an embodiment of the present invention includes the following components in mass fractions: 900 parts of fructo-oligosaccharides and 100 parts of galacto-oligosaccharides.
- a prebiotic composition according to an embodiment of the present invention includes the following components in mass fractions: 700 parts of fructo-oligosaccharides and 300 parts of galacto-oligosaccharides.
- a prebiotic composition according to an embodiment of the present invention includes the following components in mass fractions: 500 parts of fructo-oligosaccharides and 500 parts of galacto-oligosaccharides.
- a prebiotic composition according to an embodiment of the present invention includes the following components in mass fractions: 300 parts of fructo-oligosaccharides and 700 parts of galacto-oligosaccharides.
- a prebiotic composition according to an embodiment of the present invention comprises the following components in mass fractions: 100 parts of fructo-oligosaccharides and 900 parts of galacto-oligosaccharides.
- Comparative example 1 is to prepare fructooligosaccharide solution.
- fructooligosaccharide solution described in this comparative example is as follows:
- fructo-oligosaccharide solution Take 1000 g of fructo-oligosaccharide, sieve it, add physiological saline to dissolve it, the mass percentage concentration is 75%, and finally, sterilize to obtain the fructo-oligosaccharide solution.
- Comparative example 2 is to prepare galacto-oligosaccharide solution.
- the preparation method of galacto-oligosaccharide solution described in this comparative example is as follows:
- the embodiment of the present invention explores the application of the prebiotic composition in the preparation of obesity-improving products, which includes the following content:
- mice Take 80 male C57BL/6 mice aged 5 weeks, with an average body weight of 22 ⁇ 2g, SPF grade, and feed them with normal feed for one week. 10 rats, the normal group (N) was fed with common feed, and the other groups were fed with 60% high-fat feed. The mice in the normal group (N) and the model group (M) were infused with 0.2 mL of normal saline every day, and the positive control group (Y) was infused with orlistat in a normal saline solution at a dose of 120 mg orlistat/kg/d.
- the low-dose fructo-oligosaccharide group (FL) was poured into the fructo-oligosaccharide solution prepared in Comparative Example 1 according to the dose of 1.7g/kg/d, and the high-dose fructo-oligosaccharide group (FH) was poured into the fructo-oligosaccharide solution according to the dose of 8.5g/kg/d.
- the fructo-oligosaccharide solution that ratio 1 makes galacto-oligosaccharide low-dose group (GL) pours into the galacto-oligosaccharide solution that comparative example 2 makes according to 1.7g/kg/d dosage, galacto-oligosaccharide high-dose group ( GH) according to the dose of 8.5g/kg/d into the galacto-oligosaccharide solution prepared in Comparative Example 2, the prebiotic composition group (S) according to the dose of 8.5g/kg/d into the galacto-oligosaccharide solution prepared in Example 1-5
- the treatment time is 6 weeks by gavage.
- the mouse body weight gain of the prebiotic composition group (S) and the mouse body weight gain of the positive control group (Y) remain the same, and both can significantly reduce the body weight of the model group mice Increment; the low-dose fructo-oligosaccharide group (FL) is greater than the high-dose fructo-oligosaccharide group (FH) increase in mouse body weight, while the low-dose galacto-oligosaccharide group (GL) is less than the increase in mouse body weight in the low-dose oligosaccharide group Galacto-oligosaccharide high-dose group (GH), indicating that individual fructo-oligosaccharides or galacto-oligosaccharides reduce body weight gain in mice is not a simple dose-dependent relationship.
- the mouse epididymis fat index of the prebiotic composition group (S) and the mouse epididymis fat index of the positive control group (Y) remain flat, both of which can significantly reduce the model group mice Epididymis index;
- Low-dose fructo-oligosaccharide group (FL) and low-dose galacto-oligosaccharide group (GL) are better than high-dose fructo-oligosaccharide group (FH) and high-dose galacto-oligosaccharide in reducing the fat index of mice
- group (GH) on reducing the epididymis fat index in mice shows that the epididymis fat index does not decrease with the dose increase of fructo-oligosaccharide or galacto-oligosaccharide.
- the Lee index of the mice in the prebiotics composition group (S) remains the same as the Lee index of the mice in the positive control group (Y), both of which can significantly reduce the Lee index of the model group mice ;
- Fructo-oligosaccharide low-dose group (FL) and galacto-oligosaccharide low-dose group (GL) are slightly better than fructo-oligosaccharide high-dose group (FH) and galacto-oligosaccharide high-dose group ( GH) to the reducing effect of mouse Lee index.
- Example 1 in which the contents of serum lipopolysaccharide and serum D-lactic acid in the composition are the smallest Obtained composition 1 and normal group, model group, positive control group, fructo-oligosaccharide low-dose group, fructo-oligosaccharide high-dose group, galacto-oligosaccharide low-dose group, galacto-oligosaccharide high-dose group are drawn into a histogram, The obtained serum lipopolysaccharide content is shown in FIG. 4 , and the serum D-lactic acid content is shown in FIG. 5 .
- the prebiotic composition group (S) has a certain reduction effect on serum lipopolysaccharide and serum D-lactic acid, and can significantly reduce serum lipopolysaccharide and serum D-lactic acid in the model group mice. lactic acid content.
- the prebiotic composition can significantly reduce the weight gain of the model group mice, reduce the epididymis index and Lee index of the model group mice, reduce the serum lipopolysaccharide and serum D of the model group mice.
- the content of lactic acid and the reduction of body weight gain, epididymis index, Lee index, serum lipopolysaccharide content, serum D-lactic acid content and the weight of fructooligosaccharides and galactooligosaccharides in the prebiotic composition
- the data in Table 1 shows that in the prebiotic composition 1 to prebiotic composition 5 prepared in Examples 1 to 5, when 900 parts of fructo-oligosaccharides and 100 parts of galacto-oligosaccharides are used, the The decrease in body weight gain, epididymis index, Lee index, serum lipopolysaccharide content, and serum D-lactic acid content was the largest overall.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种益生元组合物及其应用，所述益生元组合物包括低聚果糖和低聚半乳糖。所述益生元组合物能用于制备改善肥胖的产品、降低血清脂多糖和血清D-乳酸的产品、降低体重增量的产品、降低附睾脂肪的产品、用于新兴微生态医疗领域的产品。
Description
本发明属于生物技术领域，尤其涉及一种益生元组合物及其应用。
肥胖是一种慢性、复杂的疾病，与当前社会中常见的疾病如高脂血症、2型糖尿病、脂肪肝、心血管疾病、癌症等密切相关。脂肪过度积累对机体新陈代谢、生理活动和心理健康会产生不利影响。因此，减肥和预防肥胖是许多慢性疾病管理的重要研究领域。
长期以来，人们一直在探索肥胖的预防及治疗手段。奥利司他(Orlistat)是目前较流行的减肥产品，于1998年在欧洲获批，是唯一获得FDA批准的长期治疗肥胖的药物，可抑制胃肠道和胰腺脂肪酶，阻断甘油三酯的水解，减少摄入脂肪的吸收。但在降低体重的同时，伴有一些如大便失禁、排便过度、油性大便等不可避免的副作用，还需要补充脂溶性维生素以避免维生素缺乏，还会降低肠道微生物多样性和丰富度。
为避免药物减肥的副作用，需要考虑通过另外的方式来控制肥胖。益生元是被微生物选择性利用从而赋予宿主健康效益的一类物质，包括低聚果糖(Fructooligosaccharides,FOS)、低聚半乳糖(Galactooligosaccharides,GOS)等。定期摄入低聚果糖和低聚半乳糖等益生元会使肠道菌群产生的短链脂肪酸增多，增加释放消除脂肪的肽类。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种能用于制备改善肥胖的产品、降低血清脂多糖和血清D-乳酸的产品、降低体重增量的产品、降低附睾脂肪的产品、用于新兴微生态医疗领域的产品的益生元组合物。
为实现上述目的，本发明采取的技术方案为：一种益生元组合物，其包括 低聚果糖和低聚半乳糖。
采用本发明的技术方案得到的益生元组合物能用于制备改善肥胖的产品、降低血清脂多糖和血清D-乳酸的产品、降低体重增量的产品、降低附睾脂肪的产品、用于新兴微生态医疗领域的产品，这些产品能有效避免药物减肥的副作用，精准发挥益生元组合物的生理作用，克服益生元应用层面的模糊性、随意性等局限，为精准营养与新兴微生态医疗等生物医药领域的应用提供典型示范，有助于改善肥胖症的预防控制与治疗康复。
作为本发明所述益生元组合物的优选实施方式，所述低聚果糖的质量份为100～900份，所述低聚半乳糖的质量份为100～900份。
作为本发明所述益生元组合物的优选实施方式，所述低聚果糖的质量份为300～900份，所述低聚半乳糖的质量份为100～700份。
作为本发明所述益生元组合物的优选实施方式，所述低聚果糖的质量份为500～900份，所述低聚半乳糖的质量份为100～500份。
作为本发明所述益生元组合物的优选实施方式，所述低聚果糖的质量份为700～900份，所述低聚半乳糖的质量份为100～300份。
低聚果糖是一种天然活性物质，可以双向调节人体微生态平衡，是典型的超强双歧因子；低聚半乳糖是人体肠道中双歧杆菌、嗜酸性乳酸杆菌等有益菌的营养源和有效的增殖因子，可以改善人体肠道的消化吸收功能。本发明通过将低聚果糖和低聚半乳糖两者配合使用，能达到单独使用所没有的效果。对于比例的优选，主要是依据益生元组合物对各个肥胖指标的综合降低效果。其中，低聚果糖的质量份为900份而低聚半乳糖的质量份为100份的益生元组合物对各个肥胖指标的综合降低效果最优。
另外，本发明还提供了上述益生元组合物在制备改善肥胖的产品中的应用。
另外，本发明还提供了上述益生元组合物在制备降低血清脂多糖和血清D-乳酸的产品中的应用。
另外，本发明还提供了上述益生元组合物在制备降低体重增量的产品中的应用。
另外，本发明还提供了上述益生元组合物在制备降低附睾脂肪的产品中的应用。
另外，本发明还提供了上述益生元组合物在制备用于新兴微生态医疗领域的产品中的应用。
与现有技术相比，本发明具有的有益效果为：本发明提供了一种益生元组合物，其包括低聚果糖和低聚半乳糖。同时本发明还提供了上述益生元组合物在制备改善肥胖的产品中的应用、在制备降低血清脂多糖和血清D-乳酸的产品中的应用、在制备降低体重增量的产品中的应用、在制备降低附睾脂肪的产品中的应用、在制备用于新兴微生态医疗领域的产品中的应用。采用本发明的技术方案得到的益生元组合物能有效改善肥胖指标，避免药物减肥的副作用，精准发挥益生元组合物的生理作用，克服益生元应用层面的模糊性、随意性等局限，为精准营养与新兴微生态医疗等生物医药领域的应用提供典型示范，有助于改善肥胖症的预防控制与治疗康复。
图1为实施例6中益生元组合物影响肥胖小鼠模型体重增量的效果图；
图2为实施例6中益生元组合物影响肥胖小鼠模型附睾脂肪指数的效果图；
图3为实施例6中益生元组合物影响肥胖小鼠模型Lee指数的效果图；
图4为实施例6中益生元组合物影响肥胖小鼠模型血清脂多糖含量的效果图；
图5为实施例6中益生元组合物影响肥胖小鼠模型血清D-乳酸含量的效果图。
为更好的说明本发明的目的、技术方案和优点，下面将结合具体实施例对本发明作进一步说明。
实施例1
本发明实施例的一种益生元组合物，其包括以下质量分数的组分：900份低聚果糖、100份低聚半乳糖。
本实施例所述益生元组合物制备方法如下：
取低聚果糖900g、低聚半乳糖100g，将两者过筛后混合均匀，再加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得益生元组合物1。
实施例2
本发明实施例的一种益生元组合物，其包括以下质量分数的组分：700份低聚果糖、300份低聚半乳糖。
本实施例所述益生元组合物制备方法如下：
取低聚果糖700g、低聚半乳糖300g，将两者过筛后混合均匀，再加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得益生元组合物2。
实施例3
本发明实施例的一种益生元组合物，其包括以下质量分数的组分：500份低聚果糖、500份低聚半乳糖。
本实施例所述益生元组合物制备方法如下：
取低聚果糖500g、低聚半乳糖500g，将两者过筛后混合均匀，再加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得益生元组合物3。
实施例4
本发明实施例的一种益生元组合物，其包括以下质量分数的组分：300份低聚果糖、700份低聚半乳糖。
本实施例所述益生元组合物制备方法如下：
取低聚果糖300g、低聚半乳糖700g，将两者过筛后混合均匀，再加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得益生元组合物4。
实施例5
本发明实施例的一种益生元组合物，其包括以下质量分数的组分：100份低聚果糖、900份低聚半乳糖。
本实施例所述益生元组合物制备方法如下：
取低聚果糖100g、低聚半乳糖900g，将两者过筛后混合均匀，再加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得益生元组合物5。
对比例1
对比例1是制备低聚果糖溶液。
本对比例所述低聚果糖溶液的制备方法如下：
取低聚果糖1000g，过筛后加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得低聚果糖溶液。
对比例2
对比例2是制备低聚半乳糖溶液。
本对比例所述低聚半乳糖溶液的制备方法如下：
取低聚半乳糖1000g，过筛后加入生理盐水使其溶解，质量百分比浓度为75％，最后，灭菌即得低聚半乳糖溶液。
实施例6
本发明实施例探究益生元组合物在制备改善肥胖的产品中的应用，其包括以下内容：
(1)小鼠模型的建立：取雄性5周龄、平均体重22±2g、SPF级C57BL/6 小鼠80只，普通饲料喂养一周后，将80只小鼠随机分为8组，每组10只，正常组(N)饲喂普通饲料，其他组饲喂60％高脂饲料。正常组(N)和模型组(M)的小鼠每天用0.2mL生理盐水灌胃，阳性对照组(Y)依120mg奥利司他/kg/d剂量灌入奥利司他生理盐水溶液，低聚果糖低剂量组(FL)依1.7g/kg/d剂量灌入对比例1制得的低聚果糖溶液，低聚果糖高剂量组(FH)依8.5g/kg/d剂量灌入对比例1制得的低聚果糖溶液，低聚半乳糖低剂量组(GL)依1.7g/kg/d剂量灌入对比例2制得的低聚半乳糖溶液，低聚半乳糖高剂量组(GH)依8.5g/kg/d剂量灌入对比例2制得的低聚半乳糖溶液，益生元组合物组(S)依8.5g/kg/d剂量灌入实施例1-5制得的益生元组合物1-5，灌胃处理时间为6周。
(2)体重增量的计算：实验开始前禁食12h后称重，作为初始体重，最后处死前禁食12h后称重，作为最终体重，根据这两个数据计算小鼠体重增量，得到的体重增量结果如表1所示，将组合物中体重增量最少的实施例1得到的组合物1和正常组、模型组、阳性对照组、低聚果糖低剂量组、低聚果糖高剂量组、低聚半乳糖低剂量组、低聚半乳糖高剂量组绘制成柱状图，如图1所示。
从图1可以看出，益生元组合物组(S)的小鼠体重增量与阳性对照组(Y)的小鼠体重增量保持持平，两者都能显著的降低模型组小鼠的体重增量；低聚果糖低剂量组(FL)对小鼠体重的增量大于低聚果糖高剂量组(FH)，而低聚半乳糖低剂量组(GL)对小鼠体重的增量小于低聚半乳糖高剂量组(GH)，说明单独的低聚果糖或低聚半乳糖降低小鼠体重增量不是简单的剂量依赖关系。
(3)附睾指数的计算：处死小鼠后，取出完整的附睾脂肪，按照附睾脂肪指数＝附睾脂肪质量(g)/体重(g)公式计算附睾指数，得到的附睾指数结果如表1所示，将组合物中附睾指数最小的实施例1得到的组合物1和正常组、模型组、阳性对照组、低聚果糖低剂量组、低聚果糖高剂量组、低聚半乳糖低剂量组、低聚半乳糖高剂量组绘制成柱状图，如图2所示。
从图2可以看出，益生元组合物组(S)的小鼠附睾脂肪指数与阳性对照组(Y)的小鼠附睾脂肪指数保持持平，两者都能显著的减小模型组小鼠的附睾指数；低聚果糖低剂量组(FL)和低聚半乳糖低剂量组(GL)对小鼠附睾脂肪指数的降低效应优于低聚果糖高剂量组(FH)和低聚半乳糖高剂量组(GH)对小 鼠附睾脂肪指数的降低效应，说明附睾脂肪指数并不是随着低聚果糖或低聚半乳糖的剂量增加而减小的。
(4)Lee指数的计算：实验末，分别测量小鼠质量和体长，按照Lee指数＝体质量(g)^(1/3)*1000/体长(cm)计算Lee指数，得到的Lee指数结果如表1所示，将组合物中Lee指数最小的实施例1得到的组合物1和正常组、模型组、阳性对照组、低聚果糖低剂量组、低聚果糖高剂量组、低聚半乳糖低剂量组、低聚半乳糖高剂量组绘制成柱状图，如图3所示。
从图3可以看出，益生元组合物组(S)的小鼠Lee指数与阳性对照组(Y)的小鼠Lee指数保持持平，两者都能显著的减小模型组小鼠的Lee指数；低聚果糖低剂量组(FL)和低聚半乳糖低剂量组(GL)对小鼠Lee指数的降低效应略优于低聚果糖高剂量组(FH)和低聚半乳糖高剂量组(GH)对小鼠Lee指数的降低效应。
(5)血清脂多糖和血清D-乳酸含量的测量：小鼠禁食12h后摘取眼球采血，室温静置60分钟，3000rpm离心15分钟，吸取血清置小试管内，用酶联免疫吸附实验检测上清的脂多糖与D-乳酸的含量，得到的血清脂多糖和血清D-乳酸含量结果如表1所示，将组合物中血清脂多糖和血清D-乳酸的含量最小的实施例1得到的组合物1和正常组、模型组、阳性对照组、低聚果糖低剂量组、低聚果糖高剂量组、低聚半乳糖低剂量组、低聚半乳糖高剂量组绘制成柱状图，得到的血清脂多糖的含量如图4所示，血清D-乳酸的含量如图5所示。
从图4和图5可以看出，益生元组合物组(S)对血清脂多糖和血清D-乳酸都有一定的降低作用，能较明显的降低模型组小鼠血清脂多糖和血清D-乳酸的含量。
表1：益生元组合物实验数据表
从表1中可以看出，益生元组合物都能显著的降低模型组小鼠的体重增量、减小模型组小鼠的附睾指数和Lee指数、降低模型组小鼠血清脂多糖和血清D-乳酸的含量，并且益生元组合物对体重增量、附睾指数、Lee指数、血清脂多糖含量、血清D-乳酸含量的减少幅度与益生元组合物中低聚果糖和低聚半乳糖的重量份有关，表1的数据显示，在实施例1～实施例5制备得到的益生元组合物1～益生元组合物5中，当采用900份低聚果糖、100份低聚半乳糖时，其对体重增量、附睾指数、Lee指数、血清脂多糖含量、血清D-乳酸含量的减少幅度整体上最大。因此，进一步选择益生元组合物1的实验数据与正常组、模型组、阳性对照组、低聚果糖低剂量组、低聚果糖高剂量组、低聚半乳糖低剂量组、低聚半乳糖高剂量组的实验数据绘制成柱状图1～柱状图5。
从图1～图5可知，整体上来看，益生元组合物组(S)对体重增量、附睾指数、Lee指数、血清脂多糖含量、血清D-乳酸含量的影响效果与阳性对照组(Y)几乎持平，两者都能显著的降低模型组小鼠的体重增量、附睾指数、Lee指数、血清脂多糖含量和血清D-乳酸含量；同时低聚果糖低剂量组(FL)、低聚半乳糖低剂量组(GL)、低聚果糖高剂量组(FH)和低聚半乳糖高剂量组(GH)对模型组小鼠的体重增量、附睾指数、Lee指数、血清脂多糖含量和血清D-乳酸含量也有一定的效果，但整体上来评估，其效果在上述指标中没有益生元组合物组(S)对各个指数的降低效果好。此结果提示，单独的低聚果糖和低聚半乳糖也有一定的改善肥胖指标的作用，但整体没有优于益生元组合物对肥胖指标的改善。
最后应当说明的是，以上实施例以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。
Claims (10)
- 一种益生元组合物，其特征在于，包括低聚果糖和低聚半乳糖。
- 根据权利要求1所述的益生元组合物，其特征在于，所述低聚果糖的质量份为100～900份，所述低聚半乳糖的质量份为100～900份。
- 根据权利要求1所述的益生元组合物，其特征在于，所述低聚果糖的质量份为300～900份，所述低聚半乳糖的质量份为100～700份。
- 根据权利要求1所述的益生元组合物，其特征在于，所述低聚果糖的质量份为500～900份，所述低聚半乳糖的质量份为100～500份。
- 根据权利要求1所述的益生元组合物，其特征在于，所述低聚果糖的质量份为700～900份，所述低聚半乳糖的质量份为100～300份。
- 如权利要求1～5任意一项所述的益生元组合物在制备改善肥胖的产品中的应用。
- 如权利要求1～5任意一项所述的益生元组合物在制备降低血清脂多糖和血清D-乳酸的产品中的应用。
- 如权利要求1～5任意一项所述的益生元组合物在制备降低体重增量的产品中的应用。
- 如权利要求1～5任意一项所述的益生元组合物在制备降低附睾脂肪的产品中的应用。
- 如权利要求1～5任意一项所述的益生元组合物在制备用于新兴微生态医疗领域的产品中的应用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110792547.XA CN113476463A (zh) | 2021-07-13 | 2021-07-13 | 一种益生元组合物及其应用 |
| CN202110792547.X | 2021-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023284778A1 true WO2023284778A1 (zh) | 2023-01-19 |
Family
ID=77939224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/105423 WO2023284778A1 (zh) | 2021-07-13 | 2022-07-13 | 一种益生元组合物及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113476463A (zh) |
| WO (1) | WO2023284778A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476463A (zh) * | 2021-07-13 | 2021-10-08 | 量子高科(广东)生物有限公司 | 一种益生元组合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945589A (zh) * | 2007-12-21 | 2011-01-12 | 荷兰纽迪希亚公司 | 用于改善肠道微生物群的非消化性碳水化合物的用途 |
| CN110708969A (zh) * | 2017-05-23 | 2020-01-17 | 北京瑞千景科技发展有限公司 | 改善营养代谢肠功能及微生态的抗炎组合物和食品及应用 |
| CN113476463A (zh) * | 2021-07-13 | 2021-10-08 | 量子高科(广东)生物有限公司 | 一种益生元组合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111838683A (zh) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | 一种含有人乳低聚糖的益生元组合物及其应用 |
-
2021
- 2021-07-13 CN CN202110792547.XA patent/CN113476463A/zh active Pending
-
2022
- 2022-07-13 WO PCT/CN2022/105423 patent/WO2023284778A1/zh unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945589A (zh) * | 2007-12-21 | 2011-01-12 | 荷兰纽迪希亚公司 | 用于改善肠道微生物群的非消化性碳水化合物的用途 |
| CN110708969A (zh) * | 2017-05-23 | 2020-01-17 | 北京瑞千景科技发展有限公司 | 改善营养代谢肠功能及微生态的抗炎组合物和食品及应用 |
| CN113476463A (zh) * | 2021-07-13 | 2021-10-08 | 量子高科(广东)生物有限公司 | 一种益生元组合物及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| LI YAN-LI,LI QIAN,HUO GUI-CHENG: "Study on Probiotic Function of Fructooligosaccharides and Galacto–oligosaccharides on Intestinal Microflora", THE FOOD INDUSTRY, vol. 33, no. 8, 20 August 2012 (2012-08-20), pages 73 - 76, XP093024802 * |
| YANG HAI-YAN;GE SHENG: "Effects of Dietary Fiber on Intestinal Microecology Related to Obesity", FOOD AND NUTRITION IN CHINA, vol. 26, no. 9, 15 July 2020 (2020-07-15), pages 12 - 16, XP093024803, DOI: 10.19870/j.cnki.11-3716/ts.20200713.002 * |
| YANG SHULIANG, XI FENG; HAO ZHIFANG: "Advances in the diagnosis and treatment of intestinal mucosal barrier injury ", CLINICAL FOCUS, vol. 24, no. 4, 20 February 2009 (2009-02-20), pages 349 - 352, XP093024812 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113476463A (zh) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blaak et al. | Short chain fatty acids in human gut and metabolic health | |
| Geng et al. | The links between gut microbiota and obesity and obesity related diseases | |
| Beserra et al. | A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity | |
| Finnerty et al. | The surgically induced stress response | |
| Mekkes et al. | The development of probiotic treatment in obesity: a review | |
| Alles et al. | Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes | |
| Delgado et al. | Immunomodulatory effects of fructans | |
| Delgado et al. | The putative effects of prebiotics as immunomodulatory agents | |
| BR112012008005B1 (pt) | composição compreendendo cepas de lactobacillus plantarum | |
| BRPI0611020A2 (pt) | uso de polidextrose para estimular os atributos funcionais de oligossacarìdeos do leite humano em crianças pequenas alimentadas com fórmula | |
| BR112012030765B1 (pt) | composição líquida estéril com caseína e fibra alimentar | |
| JP2023100870A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| WO2023284848A1 (zh) | 一种高蔗果三糖含量低聚果糖及其应用 | |
| WO2023284778A1 (zh) | 一种益生元组合物及其应用 | |
| Xin-Zhong et al. | Effect of dietary oat β-glucan on high-fat diet induced obesity in HFA mice | |
| Wan et al. | Efficacy of dietary supplements targeting gut microbiota in the prevention and treatment of gestational diabetes mellitus | |
| US11554131B2 (en) | Mixture of HMOs for treating autoimmune diseases | |
| Hascoët et al. | Use of a liquid supplement containing 2 human milk oligosaccharides: the first double-blind, randomized, controlled trial in pre-term infants | |
| Gaillard et al. | Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series | |
| Li et al. | Enhancing butyrate biosynthesis in the gut for health benefits | |
| Gao et al. | Importance of gut microbiota in health and diseases of new born infants | |
| CN109908165A (zh) | 一种含有雷公藤红素的组合物及其应用 | |
| CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
| EP3866615B1 (en) | Dietary supplement for treating dysbiosis | |
| CN112384079A (zh) | 用于治疗腹泻的营养组合物、其制备和治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22841411 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |